Last updated: September 24, 2026
Taliglucerase alfa, marketed as Elelyso, is a plant-cell-expressed recombinant glucocerebrosidase for long-term enzyme-replacement therapy in Gaucher disease. Protalix BioTherapeutics owns the product and commercial rights after Pfizer’s withdrawal from the collaboration. The drug remains commercially relevant in a concentrated rare-disease market, but its growth is constrained by established enzyme-replacement therapies, oral substrate-reduction therapy, limited patient numbers, and the expiration of U.S. biologic exclusivity in 2024.
Protalix does not report Elelyso revenue as a consistently separate global line item. Its financial trajectory must therefore be assessed through reported product sales, collaboration revenue, geographic licensing arrangements, and the company’s overall commercial portfolio.
What is taliglucerase alfa and how is Elelyso used?
Taliglucerase alfa is a recombinant form of human lysosomal acid beta-glucocerebrosidase. It is produced in genetically modified carrot cells rather than mammalian or microbial expression systems. The product is administered by intravenous infusion.
The U.S. Food and Drug Administration approved Elelyso on May 1, 2012, for adults with Gaucher disease type 1. The label was later expanded to pediatric patients aged 4 years and older. Gaucher disease type 1 is a lysosomal storage disorder caused by deficient glucocerebrosidase activity, resulting in glucosylceramide accumulation in macrophages.
| Product attribute |
Taliglucerase alfa |
| Brand |
Elelyso |
| Active ingredient |
Taliglucerase alfa |
| Sponsor and manufacturer |
Protalix BioTherapeutics |
| U.S. regulatory pathway |
Biologics license application |
| FDA approval |
May 1, 2012 |
| Initial indication |
Adults with Gaucher disease type 1 |
| Pediatric indication |
Patients aged 4 years and older |
| Administration |
Intravenous infusion |
| Therapeutic class |
Enzyme-replacement therapy |
| Production platform |
Plant-cell expression |
| Primary competitors |
Cerezyme, VPRIV, Cerdelga |
The plant-cell manufacturing platform was a central differentiator at launch. Commercially, however, physicians and payers generally evaluate Elelyso against clinical familiarity, supply reliability, dosing, infusion logistics, price, and patient switching costs rather than expression technology alone.
How large is the taliglucerase alfa market?
The addressable market is limited by the prevalence of Gaucher disease and the small number of diagnosed patients receiving treatment. Gaucher disease is considered a rare disorder, with type 1 representing the majority of diagnosed cases in North America and Europe.
The market is divided among:
- Intravenous enzyme-replacement therapies.
- Oral substrate-reduction therapies.
- Government-funded rare-disease programs.
- Hospital and specialty-pharmacy channels.
- Regional tenders, particularly in Latin America and other price-sensitive markets.
Elelyso competes directly with Sanofi’s imiglucerase, marketed as Cerezyme, and Takeda’s velaglucerase alfa, marketed as VPRIV. It also competes indirectly with oral eliglustat, marketed as Cerdelga by Sanofi, for eligible patients who prefer oral treatment and meet genotype, metabolism, and clinical criteria.
Cerezyme has the longest commercial history and a large installed base. VPRIV competes through a comparable enzyme-replacement approach and established specialty-care infrastructure. Elelyso’s commercial position is strongest where Protalix has direct access to government procurement, where pricing is competitive, or where supply diversification is valued.
What is the financial trajectory of Elelyso and Protalix?
Elelyso has generated recurring commercial revenue but has not become a large standalone biologics franchise comparable with Cerezyme. Pfizer’s initial commercialization arrangement gave Elelyso access to a global pharmaceutical sales infrastructure, but Pfizer later returned commercial rights to Protalix. Protalix subsequently assumed a greater role in direct commercialization and regional partnerships.
Public filings show that Protalix’s revenue has been influenced by several products and agreements, including Elelyso, Alfataliglicerase sales in Brazil, and other development or commercialization arrangements. The company does not provide a uniform, long-term Elelyso-only revenue series that permits a clean calculation of product growth.
Financial development
| Period |
Commercial and financial development |
| 2009 |
Protalix and Pfizer entered a global collaboration for taliglucerase alfa. |
| 2012 |
FDA approved Elelyso for Gaucher disease type 1. |
| 2012-2014 |
Pfizer commercialized Elelyso in the United States and selected international markets. |
| 2015 |
Pfizer and Protalix revised the collaboration structure, with Protalix regaining broader commercial control. |
| 2016 onward |
Protalix expanded direct commercialization and regional licensing arrangements. |
| 2020-2024 |
Elelyso remained a recurring revenue source, while Protalix’s total financial performance reflected its broader pipeline and partnership portfolio. |
| 2024 onward |
U.S. biologic reference-product exclusivity no longer provides the same regulatory barrier to biosimilar development. |
Protalix’s financial profile is more volatile than that of a large diversified pharmaceutical company. Product revenue is sensitive to tender timing, government purchasing, foreign exchange, distributor ordering patterns, and milestone or licensing income. Elelyso provides recurring cash generation, but the product alone is unlikely to support the valuation or earnings profile of a major rare-disease company.
Revenue exposure
Elelyso’s economic value comes from three sources:
- Direct product sales in territories controlled by Protalix.
- Regional sales and distribution agreements.
- Manufacturing and commercialization economics associated with Brazil and other public-sector markets.
Brazil is strategically important because Protalix has supplied taliglucerase alfa through an arrangement involving Instituto de Tecnologia em Imunobiológicos, known as Bio-Manguinhos, a unit of Fiocruz. The Brazilian relationship gives the product access to a national public-health procurement system and reduces dependence on U.S. commercial sales.
What patents protect taliglucerase alfa?
Taliglucerase alfa is protected by a combination of biologic manufacturing, cell-line, recombinant-protein, formulation, and process patents rather than a single small-molecule composition patent.
The relevant intellectual-property categories include:
- Recombinant glucocerebrosidase molecules.
- Plant-cell expression systems.
- Genetically modified carrot-cell lines.
- Methods for producing glucocerebrosidase in plant cells.
- Purification and glycosylation-control processes.
- Formulations and stable pharmaceutical compositions.
- Therapeutic use in Gaucher disease.
Because taliglucerase alfa is a biologic, patent protection must be analyzed separately from FDA regulatory exclusivity. A patent may cover a manufacturing method or formulation without blocking every biosimilar product. Conversely, the expiration of a patent does not itself create FDA approval rights for a competing biologic.
Patent strength
The strongest potential barriers are likely to be process and manufacturing patents that cover the specific plant-cell production platform or commercially relevant production steps. Those rights may create practical entry costs even when a biosimilar developer can design around individual claims.
The estate is less straightforward than the patent estate for a conventional small molecule. Key risk factors include:
- Whether issued claims cover the commercial production process.
- Whether claims survive inter partes review or district-court litigation.
- Whether a biosimilar sponsor can use a non-infringing cell line.
- Whether glycosylation and purification claims are broad enough to cover alternative manufacturing methods.
- Whether formulation claims materially restrict substitution.
- Whether patents are listed in the FDA’s Purple Book-related biologic records or appear only in general patent databases.
When did taliglucerase alfa lose U.S. biologic exclusivity?
The FDA approved Elelyso on May 1, 2012. Under the Biologics Price Competition and Innovation Act, a reference biological product generally receives 12 years of reference-product exclusivity. The principal U.S. exclusivity period therefore reached its statutory endpoint in 2024, subject to the treatment of any applicable pediatric extension.
Regulatory exclusivity does not equal patent expiry. A biosimilar applicant may face patent disputes after reference-product exclusivity ends, and Protalix may still rely on patents, manufacturing complexity, commercial contracts, and physician familiarity.
| Protection type |
Approximate status |
| FDA approval |
Active |
| Reference-product exclusivity |
Reached the 12-year period in 2024 |
| Orphan-drug exclusivity |
Expired years after the 2012 approval period |
| Patent protection |
Depends on individual claims, jurisdictions, and expiration dates |
| Biosimilar substitution |
Requires FDA approval; no automatic substitution without interchangeability designation |
What is the FDA and Orange Book status of Elelyso?
Elelyso is regulated as a biologic under a BLA, not as a conventional drug under an abbreviated new drug application. It is therefore not principally evaluated through the Orange Book framework used for small-molecule drugs.
The relevant regulatory reference is the FDA’s biologics framework, including the Purple Book and the biosimilar approval pathway. A biosimilar applicant would submit a 351(k) application and would need to demonstrate biosimilarity to the reference product. Interchangeability would require an additional showing under the applicable FDA standard.
The absence of an Orange Book listing does not mean that Elelyso lacks intellectual-property protection. It means the product’s regulatory and patent-linkage analysis differs from that of a small-molecule drug such as eliglustat.
Which companies are challenging taliglucerase alfa?
No major public U.S. biosimilar challenge to Elelyso has established a commercial launch as of the latest broadly available regulatory information. The competitive threat comes primarily from existing Gaucher therapies rather than from an approved taliglucerase alfa biosimilar.
Potential challengers include:
- Large biologics manufacturers with enzyme-replacement manufacturing capabilities.
- Regional producers seeking government-tender access.
- Companies developing follow-on glucocerebrosidase products.
- Existing Gaucher competitors pursuing switching programs or lower-cost contracting.
The commercial threshold for entry is high. A biosimilar developer would need to establish a reliable cell line, characterize glycosylation and biological activity, conduct comparability work, navigate patent exposure, and obtain payer and specialist acceptance in a small market.
What generic or biosimilar launch risks exist?
Traditional generic entry is not available for taliglucerase alfa because it is a biologic. The relevant threat is biosimilar entry.
Biosimilar risk assessment
| Risk factor |
Effect on Elelyso |
| 2024 end of reference exclusivity |
Increases regulatory entry potential |
| Small patient population |
Limits expected return on development investment |
| Complex plant-cell manufacturing |
Raises technical and validation costs |
| Infusion-based treatment |
Makes clinical switching more deliberate |
| Existing ERT competition |
Reduces the size of the conversion opportunity |
| Regional public tenders |
Can accelerate price erosion |
| Patent and process rights |
May delay or complicate launch |
| Lack of automatic substitution |
Slows pharmacy-level replacement |
The most credible near-term pricing risk may come from tender competition and negotiated discounts rather than an immediate U.S. biosimilar launch. Gaucher patients are managed by specialist physicians, and treatment continuity is important. This favors incumbent products unless a competitor offers a meaningful price or supply advantage.
How does Elelyso compare with Cerezyme, VPRIV and Cerdelga?
| Product |
Ingredient |
Route |
Position in market |
| Elelyso |
Taliglucerase alfa |
Intravenous |
Plant-cell-produced enzyme replacement; Protalix |
| Cerezyme |
Imiglucerase |
Intravenous |
Long-established enzyme-replacement product; Sanofi |
| VPRIV |
Velaglucerase alfa |
Intravenous |
Competing enzyme replacement; Takeda |
| Cerdelga |
Eliglustat |
Oral |
Substrate-reduction therapy; genotype and metabolism restrictions |
Elelyso’s principal advantage is a differentiated manufacturing platform combined with an established clinical profile. Its disadvantages are a smaller commercial footprint, less historical physician familiarity than Cerezyme, and dependence on a relatively concentrated company.
Cerdelga changes the competitive equation because it can eliminate infusion visits for eligible patients. It is not a universal substitute. Treatment depends on disease characteristics, CYP2D6 status, drug interactions, tolerability, and physician judgment.
What licensing deals affect taliglucerase alfa?
The original Pfizer collaboration was the most important licensing transaction in Elelyso’s history. Pfizer provided global commercial scale while Protalix contributed the product and manufacturing technology. The parties later altered the arrangement, allowing Protalix to regain broader rights.
The Bio-Manguinhos relationship is commercially significant because it connects taliglucerase alfa with Brazil’s public healthcare system. Government supply agreements can provide volume visibility but may compress price and create dependence on procurement cycles.
The value of these agreements should be assessed through:
- Territory retained by Protalix.
- Transfer-price and royalty terms.
- Minimum purchase commitments.
- Manufacturing obligations.
- Tender duration.
- Termination rights.
- Foreign-exchange exposure.
- Product supply guarantees.
What patent litigation and settlement risks affect Elelyso?
Publicly visible litigation risk has been lower than for many high-revenue biologics. The absence of a major disclosed Paragraph IV case is expected because Paragraph IV is a Hatch-Waxman mechanism for small-molecule products and does not directly govern biologic biosimilar applications.
A biosimilar dispute would more likely involve:
- Patent infringement litigation under the BPCIA framework.
- Declaratory-judgment proceedings.
- Manufacturing-process patents.
- Cell-line and glycosylation claims.
- Licensing negotiations.
- Confidential settlement agreements.
Any settlement could include a negotiated launch date, a license to selected patents, manufacturing restrictions, or regional carve-outs. Without a public biosimilar filing, there is no established settlement date or authorized early-entry date to model.
What generic launch scenarios should investors model?
Base case: stable niche franchise
Protalix retains the majority of existing patients and government contracts. Revenue remains recurring but grows slowly. Price pressure is manageable, and Elelyso continues to contribute cash flow without becoming a major growth engine.
Downside case: tender and switching pressure
Government buyers use competitive bidding to reduce price. Existing patients are selectively switched to lower-cost enzyme replacement or oral therapy. Elelyso revenue declines even without a biosimilar.
Biosimilar case: delayed U.S. entry
A biosimilar sponsor completes development but faces patent or manufacturing barriers. U.S. entry occurs several years after the end of regulatory exclusivity. Revenue erosion is initially limited by specialist prescribing and the absence of automatic substitution.
Accelerated-entry case
A biosimilar or follow-on product obtains approval and launches with aggressive pricing in public-sector markets. Protalix faces immediate tender pressure, especially in regions where reimbursement is centralized.
How strong is the taliglucerase alfa commercial and patent estate?
Elelyso has a defensible but specialized position.
Its commercial strengths are:
- FDA approval and long-term clinical use.
- A validated manufacturing platform.
- Established supply relationships.
- Protalix’s direct control of the product.
- Access to Brazil and other public-sector channels.
- High switching friction in chronic enzyme-replacement treatment.
Its commercial weaknesses are:
- A small underlying patient population.
- Limited public disclosure of product-level revenue.
- Dependence on a single lead commercial asset.
- Competition from two established enzyme-replacement products.
- Competition from oral substrate-reduction therapy.
- Greater biosimilar exposure after the 2024 exclusivity milestone.
Its patent strengths depend on claim scope and remaining term. Manufacturing patents can be valuable, but their practical impact depends on whether competitors can design around them. The product’s most durable barrier is likely the combined effect of technical manufacturing requirements, specialist adoption, supply reliability, and regional contracting rather than one dominant patent.
Key Takeaways
- Taliglucerase alfa is a commercially established but niche Gaucher disease biologic.
- Protalix is the central economic beneficiary after Pfizer’s withdrawal from broad commercial control.
- Elelyso revenue is recurring, but Protalix does not provide a clean, consistently reported product-only revenue series.
- Brazil and public-sector procurement are important to the product’s commercial durability.
- U.S. reference-product exclusivity reached its 12-year endpoint in 2024.
- The relevant regulatory framework is the Purple Book and the 351(k) biosimilar pathway, not the Orange Book.
- No approved U.S. biosimilar has created a confirmed commercial launch threat in the available public record.
- The main competitive products are Cerezyme, VPRIV and Cerdelga.
- Manufacturing complexity and specialist treatment patterns may delay biosimilar penetration.
- Long-term revenue risk is more likely to arise first from tender pricing, oral-therapy switching and competitive contracting than from immediate generic-style substitution.
FAQs
Is taliglucerase alfa still commercially available?
Yes. Elelyso remains an FDA-approved treatment for Gaucher disease type 1 and is marketed by Protalix through direct and regional commercial arrangements.
Is Elelyso interchangeable with Cerezyme or VPRIV?
No automatic interchangeability should be assumed. Each product is a distinct biologic, and treatment switching is determined by the prescriber, clinical factors, payer policy and supply considerations.
Does Elelyso have an Orange Book patent listing?
Elelyso is a biologic regulated under a BLA, so the Orange Book is not the primary source for its regulatory exclusivity or patent analysis. The Purple Book and individual patent records are more relevant.
Can a company launch a generic version of taliglucerase alfa?
A conventional generic cannot be approved for taliglucerase alfa. A competing company would need to pursue the FDA biosimilar pathway or another applicable biologic approval route.
Is Protalix financially dependent on Elelyso?
Elelyso is an important recurring commercial product, but Protalix’s reported financial results also include other products, partnerships and regional arrangements. Product-level revenue concentration should be assessed from each annual filing rather than inferred from total company revenue.
References
- U.S. Food and Drug Administration. (2012). FDA approves new treatment for Gaucher disease. https://www.fda.gov
- U.S. Food and Drug Administration. (2024). Elelyso prescribing information. https://www.accessdata.fda.gov
- U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov
- Protalix BioTherapeutics, Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission. https://www.sec.gov
- U.S. Food and Drug Administration. (2017). FDA approves Cerdelga for the treatment of Gaucher disease type 1. https://www.fda.gov
- Sanofi. (2024). Cerezyme prescribing information. https://www.cerezyme.com
- Takeda Pharmaceuticals. (2024). VPRIV prescribing information. https://www.vpriv.com
- U.S. Congress. (2010). Patient Protection and Affordable Care Act, Title VII: Biologics Price Competition and Innovation Act. https://www.congress.gov
